{"id":413135,"date":"2021-01-12T09:03:32","date_gmt":"2021-01-12T14:03:32","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=413135"},"modified":"2021-01-12T09:03:32","modified_gmt":"2021-01-12T14:03:32","slug":"rising-protocol-design-complexity-is-driving-rapid-growth-in-clinical-trial-data-volume-according-to-tufts-center-for-the-study-of-drug-development","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/rising-protocol-design-complexity-is-driving-rapid-growth-in-clinical-trial-data-volume-according-to-tufts-center-for-the-study-of-drug-development\/","title":{"rendered":"Rising Protocol Design Complexity Is Driving Rapid Growth in Clinical Trial Data Volume, According to Tufts Center for the Study of Drug Development"},"content":{"rendered":"

\nNew Tufts Center for the Study of Drug Development Study Updates and Expands Earlier Benchmarks
\n<\/h2>\n
\n

BOSTON, Jan. 12, 2021 (GLOBE NEWSWIRE) — Ever more complex clinical trial designs are collecting much higher volumes of data from a variety of sources, intensifying pressure on drug sponsors to meet speed and efficiency goals, according to the Tufts Center for the Study of Drug Development<\/a>.<\/p>\n

Phase III clinical trials currently generate an average of 3.6 million data points, three times the data collected by late stage trials 10 years ago, according to a newly completed study from Tufts CSDD.<\/p>\n

\u201cWhat we\u2019re seeing is the consequence of biopharmaceutical companies engaging in more ambitious and customized drug development activity that targets a growing number of rare diseases, stratifies participant subgroups using biomarker and genetic data, and relies on more structured and unstructured patient data from a larger number of sources,\u201d said Ken Getz, professor and director of Tufts CSDD.<\/p>\n

He added that clinical trial designs are expected to become more complex in the future, generating even greater data volume and diversity.<\/p>\n

\u201cDrug developers will be compelled to further leverage data management strategies and tactics\u2014including real-time interim assessment, risk-based approaches, automation, and augmented analytics\u2014to support scientific and operating decisions,\u201d Getz said.<\/p>\n

The new study updates earlier benchmarks and establishes a number of new baseline measures. The research was based on 220 recently completed protocols targeting multiple therapeutic areas worldwide.<\/p>\n

Other key findings from the study, summarized in the January\/February Tufts CSDD Impact Report<\/em><\/a>, released today, include the following:<\/p>\n